Does, or will, BMY have the same ability to pre-determine, pre-select the correct patient with enough targets to permit successful treatment with its Opdivo as Merck now seems to possess for its Keytruda?
But the patients that do not have enough of such targets still will not likely have enough RRRs, remaining at 20-25%. Now we await PPHM, and whether its Bavi has the ability to increase those RRRs %s.
The question also remains in my mind whether those PFSs and pCRs and cCRs are of a lasting nature, or whether remission is still possible/likely.
What will be the effect of Bavi in those situations?
Per jakedogman: "the landscape has changed and how well does bavi help others is the question that is being asked..."
Per Dr Brekken: ..."died of old age"?
I bet AZN is interested in answer.
Market Data 
Markets 
AI
